These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23286841)

  • 61. Barriers to hepatitis C treatment.
    McGowan CE; Fried MW
    Liver Int; 2012 Feb; 32 Suppl 1(0 1):151-6. PubMed ID: 22212587
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Acute pancreatitis associated with boceprevir: a case report.
    Bilar JM; Carvalho-Filho RJ; Mota CF; Fucuta Pda S; Ferraz ML
    Braz J Infect Dis; 2014; 18(4):454-6. PubMed ID: 24833196
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Emerging therapeutic options for the management of hepatitis C infection.
    Thompson JR
    World J Gastroenterol; 2014 Jun; 20(23):7079-88. PubMed ID: 24966581
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Response-guided and -unguided treatment of chronic hepatitis C.
    Reddy KR; Lin F; Zoulim F
    Liver Int; 2012 Feb; 32 Suppl 1():64-73. PubMed ID: 22212575
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection.
    Chayama K; Mitsui F; Hayes CN
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):21-30. PubMed ID: 25220206
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Current status of treatment for chronic hepatitis C virus infection.
    Talwani R; Gilliam BL; Rizza SA; Nehra V; Temesgen Z
    Drugs Today (Barc); 2012 Mar; 48(3):219-31. PubMed ID: 22462041
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [New therapeutic strategies in chronic hepatitis C].
    Pawlotsky JM
    Gastroenterol Clin Biol; 2006; 30(8-9):1009-11. PubMed ID: 17075451
    [No Abstract]   [Full Text] [Related]  

  • 68. Boceprevir.
    Rizza SA; Talwani R; Nehra V; Temesgen Z
    Drugs Today (Barc); 2011 Oct; 47(10):743-51. PubMed ID: 22076489
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Interferon-combination strategies for the treatment of chronic hepatitis C.
    Aronsohn A; Jensen D
    Semin Liver Dis; 2014 Feb; 34(1):30-6. PubMed ID: 24782256
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals.
    Jazwinski AB; Muir AJ
    Gastroenterol Clin North Am; 2011 Sep; 40(3):481-94. PubMed ID: 21893269
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?
    Grasso A; Malfatti F; Testa R
    World J Gastroenterol; 2013 Nov; 19(41):6947-56. PubMed ID: 24222938
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recent development of therapeutics for chronic HCV infection.
    Huang Z; Murray MG; Secrist JA
    Antiviral Res; 2006 Sep; 71(2-3):351-62. PubMed ID: 16828888
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Treatment of chronic hepatitis C in HIV coinfection].
    Boesecke C; Rockstroh JK
    MMW Fortschr Med; 2012 May; 154 Suppl 1():42-4. PubMed ID: 22916601
    [No Abstract]   [Full Text] [Related]  

  • 74. Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage?
    Talavera Pons S; Lamblin G; Boyer A; Sautou V; Abergel A
    Eur J Clin Pharmacol; 2014 Jul; 70(7):775-89. PubMed ID: 24817413
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Screening, diagnosis and treatment of chronic hepatitis C in clinical practice].
    Ridruejo E; Fainboim H; Villamil A
    Medicina (B Aires); 2016; 76(6):390-398. PubMed ID: 27959851
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [The 6th International Hepatology Congress "White Nights of Hepatology", Saint-Petersburg, June 2014].
    Golovanova EV
    Eksp Klin Gastroenterol; 2014; (7):98-100. PubMed ID: 25842413
    [No Abstract]   [Full Text] [Related]  

  • 77. Breakthroughs in hepatitis C research: from discovery to cure.
    Manns MP; Maasoumy B
    Nat Rev Gastroenterol Hepatol; 2022 Aug; 19(8):533-550. PubMed ID: 35595834
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.
    Maticic M; Videcnik Zorman J; Gregorcic S; Schatz E; Lazarus JV
    BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S14. PubMed ID: 25252635
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sofosbuvir and ABT-450: terminator of hepatitis C virus?
    Zeng QL; Zhang JY; Zhang Z; Wang LF; Wang FS
    World J Gastroenterol; 2013 Jun; 19(21):3199-206. PubMed ID: 23745021
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Estimating the prevalence of hepatitis C infection in New York City using surveillance data.
    Balter S; Stark JH; Kennedy J; Bornschlegel K; Konty K
    Epidemiol Infect; 2014 Feb; 142(2):262-9. PubMed ID: 23657093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.